References

10.3324/haematol.2019.230771

10.3324/haematol.2019.230771 · External reference

10.1111/j.1538‐7836.2012.04654.x

10.1111/j.1538‐7836.2012.04654.x · External reference

10.1097/mbc.0b013e32832ca388

10.1097/mbc.0b013e32832ca388 · External reference

10.1055/s‐0029‐1245109

10.1055/s‐0029‐1245109 · External reference

10.1097/md.0000000000005232

10.1097/md.0000000000005232 · External reference

10.1182/blood‐2006‐06‐029850

10.1182/blood‐2006‐06‐029850 · External reference

10.1002/ajh.24777

10.1002/ajh.24777 · External reference

10.1002/1097‐0142(20010315)91:6<1067::aid‐cncr1101>3.0.co;2‐4

10.1002/1097‐0142(20010315)91:6<1067::aid‐cncr1101>3.0.co;2‐4 · External reference

10.1182/blood‐2008‐03‐143586

10.1182/blood‐2008‐03‐143586 · External reference

10.1007/s12185‐009‐0347‐9

10.1007/s12185‐009‐0347‐9 · External reference

Acquired Haemophilia as the Initial Manifestation of Colorectal Cancer Recurrence

2021 · External reference

10.1016/j.cpccr.2026.100409

10.1016/j.cpccr.2026.100409 · External reference

10.1111/hae.14481

10.1111/hae.14481 · External reference

10.1182/blood‐2012‐02‐408930

10.1182/blood‐2012‐02‐408930 · External reference

10.3390/biom15070967

10.3390/biom15070967 · External reference

10.1182/blood‐2014‐07‐587089

10.1182/blood‐2014‐07‐587089 · External reference

10.1016/j.critrevonc.2006.11.004

10.1016/j.critrevonc.2006.11.004 · External reference

10.1016/j.jtha.2022.10.004

10.1016/j.jtha.2022.10.004 · External reference

Final Analysis Results from the AGEHA Study: Emicizumab Prophylaxis for Acquired Haemophilia A with or without Immunosuppressive Therapy

10.1055/a-2384-3585 · 2025 · External reference

Early Emicizumab Treatment in Acquired Haemophilia A: Impact on Bypassing Agent Use and Length of Hospitalization in an Australian Single‐centre Cohort

10.1055/a-2622-3483 · 2026 · External reference